survival

Men Who Fail Primary Radiation Can Have Good Results After Salvage Surgery

Men who have decided to have radiation as their first (primary) treatment for prostate cancer have a one-third chance of recurrence. Some of those men have salvage radical prostatectomy (SRP)  to fight the recurrence.  A study shows this might be a good idea. Antoni Vilaseca, MD, etal from Memorial Sloan-Kettering Cancer Center in New York, studied 251 men who had a Salvage Radical Prostatectomy (SRP) after they failed their primary treatment with external beam radiation therapy, brachytherapy (seeds), or with both. The researchers evaluated long-term oncologic outcomes (survival and disease progression) of the SRP in general as well as evaluating if using minimally [...]

Xtandi In Combination with Zytiga Is Not Better Than Either Drug Alone

Often I have heard people ask why if one drug is effective we shouldn’t simply take two or three at the same time? The answer is simple, because we don’t know if combining multiple drugs will make any difference to a man’s survival. The only way we can be sure is with good evidence. Good evidence requires, in the case of drugs, doing a clinical trial to see if a certain type of combination will be beneficial. In such a late-stage clinical trial designed to see if Xtandi in addition to Zytiga along with a steroid worked any better than [...]

Oncotype DX® Now Validated for Adverse Pathology, Biochemical Recurrence, Metastasis and Prostate Cancer Specific Death

In a press release issued yesterday, Genomic Health Inc. announced topline results from their clinical validation study of its biopsy-based Oncotype DX® Genomic Prostate Score™ (GPS). The study met its primary endpoint by demonstrating that Oncotype DX® test is a strong predictor for the development of metastasis and also prostate cancer death in men with early-stage prostate cancer. The test evaluates the genetic makeup of tumor tissue taken from prostate biopsies. The Oncotype DX test has now been validated for adverse pathology, biochemical recurrence, metastasis and prostate cancer-specific death. According to a statement issued by Phil Febbo, M.D., the chief medical officer, Genomic Health, [...]

Efficacy of Enzalutamide in Castrate-Resistant Prostate Cancer in Men with Visceral Metastases

We know that men with metastatic castration-resistant prostate cancer (mCRPC) and visceral metastases have a worse prognosis than those with non-visceral metastases. The important question we need to understand is what, of our currently available treatments, might be effective for this more aggressive and deadly type of prostate cancer? Results of the phase 3 AFFIRM clinical trial have demonstrated that treatment with the androgen receptor inhibitor enzalutamide (Xtandi) resulted in significant improvements in outcomes for men with mCRPC. This blog post discusses the efficacy of enzalutamide among men from the AFFIRM trial who had visceral disease. Men who were in [...]

スーパーコピーブランド ロレックススーパーコピー オメガスーパーコピー ブルガリスーパーコピー ブライトリングスーパーコピー カルティエスーパーコピー シャネル時計コピー IWCスーパーコピー フランクミュラースーパーコピー パネライスーパーコピー タグホイヤースーパーコピー ウブロスーパーコピー ガガミラノスーパーコピー ルイヴィトンスーパーコピー シャネルスーパーコピー エルメススーパーコピー グッチスーパーコピー ボッテガヴェネタスーパーコピー プラダスーパーコピー セリーヌスーパーコピー ロレックススーパーコピー ウブロスーパーコピー